Background: Cardiogenic shock is a feared complication of acute myocardial infarction with high mortality rates. Data on the predictive role of acid base dysregulation in this clinical setting are sparse. We therefore embarked on investigating the predictive role of serum bicarbonate in critically ill intensive care unit (ICU) patients with cardiogenic shock. Methods: A total of 165 ischaemic cardiogenic shock patients (118 men, aged 68.4 years (interquartile range 59.0-77.4), APACHE II score 26.0 (interquartile range 21.0-29.0), after percutaneous coronary intervention were included in a single-centre analysis. Percutaneous coronary intervention-related data such as left ventricular ejection fraction and laboratory indices were recorded and routine clinical follow-up was obtained at hospital discharge and at one year. Allcause mortality was assessed and data were analysed using univariate and multivariate models. Results: All-cause mortality was highest (17%) during the first 48 hours following ICU admission (28-day mortality rate 43%). In a multiple regression model, age (hazard ratio (HR) 1.035, 95% confidence interval (CI) 1.011-1.059, P=0.004), APACHE II score (HR 1.036, 95% CI 1.002-1.072, P=0.037) and baseline serum bicarbonate levels (HR 0.93, 95% CI 0.866-0.998, P=0.046) independently predicted 28-day mortality (overall model fit χ 2 22.9, P<0.0001). The HR for patients in the lowest baseline serum bicarbonate tertile for 365-day mortality was HR 2.06 (95% CI 1.20-3.53).
Introduction
Cardiogenic shock (CS) develops in about 5-15% of critically ill patients with acute myocardial infarction (AMI) and in-hospital mortality rates of ischaemic heart failure remain high at 40-50%. [1] [2] [3] [4] [5] Approximately 50% of fatal outcomes typically occur during the early phase of the disease within the first 48 hours following hospital admission. Early revascularisation is thus considered the treatment of choice for AMI complicated by CS and significantly increases survival rates. 3, 4, 6 Baseline serum bicarbonate levels independently predict short-term mortality in critically ill patients with ischaemic cardiogenic shock Haemodynamic instability in critically ill patients with CS may induce imbalance of a number of systemic metabolic and neuro-humoral functions and may lead to subsequent end-organ dysfunction (such as, for example, renal dysfunction). 5 In fact, tissue hypoxia resulting from haemodynamic failure may provoke anaerobic glycolysis in end-organ tissues with consecutive systemic lactic acidosis. [7] [8] [9] [10] [11] [12] The importance of developing lactic acidosis has recently been highlighted in critically ill patients with systemic inflammatory disease presenting in septic shock. 13 Systemic acidosis may further be aggravated by reduced hepatic clearance of lactate as a consequence of diminished hepatic perfusion and/or increased venous pressure due to right ventricular dysfunction. Lactate, in particular lactate clearance and duration of lactic acidosis, predicts mortality in a general cohort of critically ill patients. 7, 8, 11, 14 Importantly, however, in CS acidosis can maintain a vicious cycle via diminished myocardial contractility and therefore aggravate haemodynamic failure. 15, 16 In addition, renal dysfunction as in acute kidney injury (AKI) may emerge early in patients with CS 5 and the development of AKI imposes significant negative effects on survival rates in critically ill patients. 17, 18 AKI potentially worsens acid-base imbalance due to reduced renal proton clearance, reduced renal bicarbonate reabsorption, and/or increased bicarbonate loss. Thus, metabolic acidosis in the setting of critically ill CS patients most often is a multifactorial event caused by systemic lactic acidosis, bicarbonate loss, mounting ketones and accumulation of inorganic acids. 16 As mortality peaks within the first 48 hours after CS onset, early detection of patients at risk is of particular importance. However, little is known about the prognostic importance of acid-base disorder in patients with CS. We therefore aimed to investigate the prognostic power of serum bicarbonate levels at intensive care unit (ICU) admission in a large cohort of critically ill patients with CS following percutaneous coronary intervention (PCI).
Methods

Study population
For inclusion into this single-centre analysis, 253 critically ill patients clinically classified as Killip IV 19 undergoing PCI were included between February 2009 and December 2012. A total of 165 patients were retained in the final data set. The study flow chart is given in Figure 1 . Recording of patient data occurred within the Cardiobase Bern PCI registry (NCT identifier: NCT002241291), which prospectively collects clinical, procedural and clinical outcome data of all patients undergoing PCI at the Bern University Hospital, Switzerland. ICU data were retrospectively collected and included in the final analysis.
For the current analysis, CS was defined in accordance with the IABP-shock II trial criteria: 20 systolic blood pressure <90 mmHg for more than 30 minutes or catecholamines required to maintain pressure >90 mmHg during systole and signs of pulmonary congestion and signs of impaired perfusion with at least one of the following criteria: (a) altered mental status; (b) cold clammy skin and extremities; (c) oliguria with urine output <30 ml/hour; (d) serum lactate >2.0 mmol/l. Recorded clinical outcome measurements included inhospital, 28 day and one year mortality and length of ICU stay. Disease severity was assessed by the APACHE II score. 21 Data from the ICU stay were retrieved from electronic patient charts (Centricity Critical Care Clinisoft; General Electrics, Helsinki, Finland). Estimated glomerular filtration rates (eGFR) were calculated using the CKD-Epi formula. 22 The study was approved by the local ethics committee on human research (KEK 137/14) and was conducted in accordance with the Declaration of Helsinki.
Blood samples were drawn from arterial lines for assessment of acid-base status (including serum bicarbonate levels). All laboratory analyses were performed in a certified laboratory of the Inselspital, University of Bern, Switzerland. Serum bicarbonate assessment was performed using routine point-of-care blood gas analysers (radiometer Copenhagen; ABL 800 Flex, Willich, Germany).
Follow-up of study patients
Patients were systematically followed at hospital discharge and at one year. Follow-up information was available in 100% of cases at hospital discharge and day 28. At day 365, follow-up data were missing in three out of the initial 165 patients (2%). Survival data were obtained from hospital records and municipal civil registries. A health questionnaire was sent to all patients alive followed by telephone contact in case of missing response. General practitioners and referring cardiologists were contacted as necessary for potential additional information.
Statistical analysis
For statistical analysis, MedCalc 12.0 Software was used (MedCalc Software, Mariakerke, Belgium). The Kolmogorov-Smirnov test was used to check for normal distribution. For between-group comparisons MannWhitney U-testing was used. Data are reported as median and interquartile range (IQR), if not indicated otherwise. Univariate followed by multivariate models including relevant clinical variables were applied for (details are given in legends). For the assessment of prediction of nonsurvival, Cox proportional hazards regression models were calculated. Kaplan-Meier cumulative survival estimate curves were constructed (Mantel Haenszel log rank P values are given). A P value less than 0.05 was considered statistically significant.
Results
Patient demographics
Patient characteristics are given in Table 1 ; 17% of patients died during the first 48 hours. Mortality within 28 days amounted to 43% and mortality rates following day 28 were low (increase by 6% until 365 days after hospitalisation, Table 1 ). In general, non-surviving patients were significantly older, had higher disease severity (as assessed by APACHE II score), and were resuscitated from out of hospital cardiac arrest more frequently (Table 1) . Left ventricular ejection fraction (LVEF) and maximal creatine kinase (CK) did not differ between survivors and nonsurvivors (Table 1) . Initial serum bicarbonate levels were lower, whereas lactate levels were higher in non-survivors (Table 1 ). In addition, pH was not found to differ between the two groups at baseline (Table 1) . Renal function assessed by eGFR and urinary output during the first 24 hours was reduced in non-survivors. No difference was noted regarding baseline serum creatinine and urea levels, potassium levels and haemoglobin levels in surviving versus non-surviving patients (Table 1) .
Univariate and multivariate predictor models
Univariate analysis identified a significant association of age, APACHE II score, peak lactate (first 24 hours), eGFR, urinary output and baseline serum bicarbonate levels with 28-day mortality (all P<0.05, hazard ratios given in Table  2 ). Markers of cardiac function and/or AMI severity including LVEF, troponin levels at baseline, maximum creatinine kinase, or creatinine-kinase-MB fraction, as well as the number of vessels affected were not found to be significantly associated with mortality in univariate models ( Table  2) . This also applied to total cholesterol, haemoglobin, serum creatinine and urea levels ( Table 2) .
Multivariate regression models/stepwise Cox proportional hazards regression revealed age (hazard ratio (HR) 
Baseline serum bicarbonate and outcome
As shown in Table 1 In these analyses, it appeared that patients in the lowest tertile of baseline serum bicarbonate had the highest risk of mortality until 28 days and until 365 days of follow-up. For illustrative purposes, Kaplan-Meier survival curves were constructed (Figure 2(a) and (b) ).
When referenced to the upper tertile, the following HRs for 365-day mortality applied: (middle tertile) HR 1.38 (95% CI 0.82-2.32), and (lower tertile) HR 2.06 (95% CI 1.20-3.53). The overall model fitness was χ 2 7.63, P=0.02 (log rank test). In explorative analyses, baseline bicarbonate levels were additionally checked for correlations with outcome indices/disease severity such as APACHE II score and length of stay (LOS) in both ICU and in hospital. A significant correlation of baseline serum bicarbonate levels with APACHE II score (Spearman's rank correlation coefficient rho −0.248, 95% CI −0.39 to −0.1, P=0.002) was noted. Nevertheless, as respective indices might be somewhat cross-linked, this should be interpreted with caution.
Follow-up and mortality
Follow-up of study patients revealed that all-cause mortality was highest during the first 48 hours following ICU admission ( Figure 2) ; 28-day and 365-day mortality rates were 43% and 49%, respectively (Table 1, Figure 2 ).
Discussion
Here we investigate indices of potential prognostic importance in critically ill patients with AMI complicated by CS. In a prospective registry with retrospective analysis including 165 critically ill patients with CS, we found that reduced baseline serum bicarbonate levels independently predicted 28-day all-cause mortality. Patients who died within 28 days after admission for CS had significantly lower baseline bicarbonate levels compared to survivors. Moreover, we observed that CS patients in the lowest tertile of serum bicarbonate levels at baseline had the highest risk of mortality. Given the widespread availability of blood gas analysers on ICUs, we propose to include baseline serum bicarbonate levels to the portfolio of prognostic biomarkers in CS patients.
The cohort under investigation represents a rather typical cohort of critically ill patients with CS. This is reflected by several indices including baseline disease severity (assessed using the APACHE II scoring system) and markers of cardiac impairment. Importantly, acid base status seems of particular interest in this patient cohort, because deranged acid base status was previously shown to affect cardiovascular performance negatively. In fact, acidosis-induced mechanisms include, among others, reduced adrenoreceptor response, decreased cardiac contractility and altered systemic vascular resistance resulting in aggravation of circulatory shock 16, 23 leading to progressive tissue hypoperfusion with consecutive cellular hypoxia and, finally, end-organ failure including AKI. 24 Therefore, acid base derangements contribute to adverse outcomes in a general population of critically ill patients. Clinically useful indices of acid base status in critically ill patients include serum bicarbonate, base excess and systemic lactate levels. 
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Variable was excluded from model as significance was not reached.
ICU: intensive care unit; CI: confidence interval; BMI: body mass index; APACHE II: Acute Physiology and Chronic Health Evaluation II score; LVEF: left ventricular ejection fraction; CK: creatine kinase; eGFR: estimated glomerular filtration rate.
Mortality risk assessment in critically ill patients with CS should occur early following ICU admission because mortality is highest during the first 48 hours following the onset of shock. Biomarkers that would allow early prognostication are therefore of high interest. Biomarkers assessing myocardial damage (i.e. peak CK/CK-MB) are key in predicting outcomes following AMI patients without CS. However, the rapid and fatal evolution of CS often does not permit peak values to be reached, making them less ideal for prognostication in CS highlighting the need for alternative and easily assessable biomarkers. 25, 26 Interestingly, our data indicate that bicarbonate but not systemic lactate levels independently predict non-survival in CS. Although this is in line with previous data from smaller analyses, 27 it may be attributable to both the limited range of lactate levels in our study patients and the fact that peak lactate levels rather than lactate clearance was assessed. Assessment of lactate clearance was previously shown to predict prognosis reliably 14 and might thus be of interest in this specific population of critically ill patients. Nevertheless, assessment of lactate clearance in this setting was out of the scope of the current analysis and should be pursued in subsequent studies. Moreover, AKI was previously associated with adverse prognosis in patients with CS 28 but did not predict mortality in our multivariate model. This result, however, may be attributable to the fact that patients in our cohort presented with rather limited degree of AKI. As the calculated eGFR does not reflect instantaneous kidney function in the setting of AKI as a dynamic condition, its use in acute CS seems therefore debatable.
Several limitations of our analysis deserve discussion. First, driven primarily by study design, we present data from a single-centre investigation deriving from a prospective registry that were analysed retrospectively. Moreover, a limited sample size was applied preventing meaningful analyses of subgroups of investigated CS patients, such as, for example, patients post-cardiac arrest. Thus, it should be noted that the degree of influence imposed by relevant comorbidities that influence acid base status (such as, for example, pre-PCI renal failure, respiratory failure, the presence of cardiac arrest, or others) remains unclear in the setting investigated here. Nevertheless, we consider our cohort to reflect a typical general population of critically ill CS patients in the coronary catheter laboratory classified as Killip IV that were clinically judged to have acute ischaemic origin of CS. Second, patients who developed CS at a later time point following PCI or those who died during PCI were not included. Our study therefore focused on patients with immediate CS. Patients who died during PCI (n=16, Figure 1) were excluded from the analysis for several reasons, including the fact that we were interested in evaluating potential prognostic relevant indices in critically ill patients at ICU admission and the inclusion of patients dying before ICU admission might most likely introduces a bias. Nevertheless, when analysing the available serum bicarbonate measurements in respective patients dying during PCI (data available from 44% of respective individuals), it appeared that serum bicarbonate levels were considerably low (median/IQR 9.8 mmol/l, 8.6-11.9). This may further underline the predictor status of serum bicarbonate in the setting investigated here. Third, in the multivariate prediction model, APACHE II scores were included. This was performed due to the fact that disease severity should be taken into account when data from critically ill patients are analysed. Nevertheless, it must be noted that some degree of co-linearity to variables such as age exists. Fourth, we used eGFR instead of measured GFR for the assessment of renal dysfunction. Both indices may be questionable in the critical care setting given the fact that, as mentioned before, kidney function is not in a steady state condition. Fifth, when interpreting serum lactate levels in the current analysis, it should be noted that only the highest (within the first 24 hours) and admittance serum lactate levels were available. Although this was beyond the scope of the current retrospective analysis, individual lactate clearance should most likely preferably be investigated in subsequent analyses. 7, 8, 12 Sixth, we observed that established prognostic cardiac (bio-)markers such as LVEF, troponins, or the number of affected vessels did not predict 28-day mortality in single predictor models for non-survival at day 28. Although we are unable to elucidate the respective underlying mechanisms for our observations, we speculate that this may be attributable to the time of sample drawing and/or the limited sample size of the cohort investigated.
In conclusion, our data suggest that baseline serum bicarbonate levels independently predict mortality in critically ill patients with CS. Given the high mortality of CS during the first 48 hours, baseline serum bicarbonate levels may help to identify patients at risk and may contribute to improved risk stratification of affected patients. We therefore propose to include baseline serum bicarbonate measurements in the portfolio of prognostic indices in critically ill patients in CS.
